Accessibility Menu
 
Mirum Pharmaceuticals logo

Mirum Pharmaceuticals

(NASDAQ) MIRM

Current Price$94.69
Market Cap$5.71B
Since IPO (2019)+599%
5 Year+359%
1 Year+115%
1 Month+5%

Mirum Pharmaceuticals Financials at a Glance

Market Cap

$5.71B

Revenue (TTM)

$521.31M

Net Income (TTM)

$23.36M

EPS (TTM)

$-0.48

P/E Ratio

-197.91

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$94.69

Volume

873,716.651

Open

$94.51

Previous Close

$94.62

Daily Range

$92.25 - $97.51

52-Week Range

$36.88 - $109.28

MIRM: Motley Fool Moneyball Superscore

75

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Mirum Pharmaceuticals

Industry

Biotechnology

Employees

372

CEO

Christopher Peetz, MBA

Headquarters

Foster City, CA 94404, US

MIRM Financials

Key Financial Metrics (TTM)

Gross Margin

81%

Operating Margin

-4%

Net Income Margin

-4%

Return on Equity

-9%

Return on Capital

-3%

Return on Assets

-3%

Earnings Yield

-0.51%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.71B

Shares Outstanding

60.34M

Volume

873.72K

Short Interest

0.00%

Avg. Volume

884.64K

Financials (TTM)

Gross Profit

$420.73M

Operating Income

$22.14M

EBITDA

$17.21M

Operating Cash Flow

$55.83M

Capital Expenditure

$954.00K

Free Cash Flow

$54.87M

Cash & ST Invst.

$383.33M

Total Debt

$319.45M

Mirum Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$148.93M

+49.8%

Gross Profit

$120.59M

+57.4%

Gross Margin

80.97%

N/A

Market Cap

$5.71B

N/A

Market Cap/Employee

$17.09M

N/A

Employees

334

N/A

Net Income

$5.73M

+75.9%

EBITDA

$4.71M

+132.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$63.88M

+270.6%

Accounts Receivable

$123.33M

+57.5%

Inventory

$24.89M

+11.1%

Long Term Debt

$317.31M

+0.4%

Short Term Debt

$2.14M

+25.2%

Return on Assets

-2.77%

N/A

Return on Invested Capital

-3.47%

N/A

Free Cash Flow

$5.47M

+207.4%

Operating Cash Flow

$6.07M

+219.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BLTEBelite Bio, Inc
$167.25+4.90%
PRAXPraxis Precision Medicines, Inc.
$319.28-0.90%
LGNDLigand Pharmaceuticals Incorporated
$199.62-0.02%
ACADACADIA Pharmaceuticals Inc.
$22.32+0.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
CYCNCyclerion Therapeutics
$6.38+3.12%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.23+0.04%
NKENike
$44.63-0.16%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.45-0.01%

Questions About MIRM

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.